review carbamazepine hematologic reactions monitoring recommendations Early case reports fatal hematologic effects CBZ extensive monitoring recommendations manufacturer rarity blood dyscrasias many authors manufacturer guidelines manufacturer specific monitoring guidelines physicians CBZ clinical judgment article case reports studies CBZ hematologic effects Due rapid daily laboratory checks necessary aplastic anemia agranulocytosis thrombocytopenia adverse effects patients physicians signs symptoms Leukopenia percent children percent adults onset first months treatment patients risk low low-normal pretreatment white blood cell WBC count Leukopenia CBZ review literature monitoring high-risk patients first months treatment frequency results laboratory value WBC neutrophil counts warrant decrease dose frequent monitoring CBZ discontinuation necessary 